Yes, though we are still faced with completing scale-up and production at the current facility to produce the materials necessary to complete the GLP study at BASi. I think it is prudent to consider that that could still potentially be a source of delay.
Tox should normally take about 6 months and then an additional few months to write up. Timing wise, that would dovetail fairly well with completion of the cGMP facility (Q1) and production of the cGMP test batches (Q2?) in preparation for human trials. So things could start to come together nicely around Q3, depending on how quickly they can scale up the existing facility to produce materials for GLP tox studies. I think it is a tough call on whether they can start human trials in Q4, but even if that were to slip a couple quarters, it doesn't change the investment thesis at all in my opinion.
News 
Market Data 
Discover 
